Pancreatic Cancer Treatment in India
Get Pancreatic Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Pancreatic Cancer Treatment in UAE
Pancreatic Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Pancreatic cancer treatment encompasses a spectrum of interventions — from curative-intent Whipple procedures and distal pancreatectomies to advanced systemic therapies including FOLFIRINOX, gemcitabine-nab-paclitaxel combinations, and precision-targeted PARP inhibitors for BRCA-mutated tumors. Resection in high-volume centers achieves 5-year survival rates of 20–25% for Stage I–II disease, while multimodal protocols for locally advanced cases continue to improve median overall survival. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed cancer hospitals in Dubai and Abu Dhabi, offering world-class surgical and oncologic expertise at a fraction of Western costs, with full end-to-end logistical support.
Hospital Stay: 7–21 days (varies by treatment modality: 7–10 days for Whipple/pancreatectomy; shorter for chemotherapy initiation cycles) • Total Stay in Country (Fit-to-Fly): 4–8 weeks post-surgery for major resection; 2–3 weeks after chemotherapy cycle initiation, subject to oncologist clearance • Success Rate: 20–25% 5-year survival for resectable (Stage I–II) disease; median overall survival of 12–18 months for locally advanced disease with multimodal therapy
What Is It?
Pancreatic cancer — most commonly pancreatic ductal adenocarcinoma (PDAC) — arises from the exocrine cells lining the pancreatic ducts and accounts for approximately 90% of all pancreatic malignancies. Because the pancreas is a deeply retroperitoneal organ with rich lymphovascular proximity to the superior mesenteric artery (SMA), portal vein, and celiac axis, early-stage disease is largely asymptomatic, resulting in over 80% of cases being diagnosed at locally advanced (Stage III) or metastatic (Stage IV) stages. Physiologically, tumor involvement disrupts both exocrine function — leading to malabsorption, steatorrhea, and significant weight loss — and endocrine function, frequently inducing new-onset diabetes mellitus. Obstructive jaundice due to common bile duct compression is a hallmark presentation in pancreatic head tumors and is managed with endoscopic retrograde cholangiopancreatography (ERCP) stenting prior to definitive surgery.
The standard staging framework relies on the AJCC 8th Edition TNM system, supplemented by radiological resectability criteria stratified into resectable, borderline resectable, and locally advanced categories per the National Comprehensive Cancer Network (NCCN) and International Study Group of Pancreatic Surgery (ISGPS) guidelines. CT pancreatic protocol (triphasic thin-slice CT), MRI/MRCP, endoscopic ultrasound (EUS) with fine-needle biopsy, and PET-CT constitute the foundational staging toolkit. Serum CA 19-9 serves as the primary tumor marker, though its utility is limited in Lewis antigen-negative patients.
Contemporary standard of care integrates multimodal strategies: surgical resection where feasible, perioperative chemotherapy (neoadjuvant and adjuvant), chemoradiation for borderline and locally advanced disease, and systemic therapy for metastatic disease. Germline and somatic molecular profiling — including BRCA1/2, PALB2, ATM, KRAS G12C, and mismatch repair (MMR) status — is now recommended for all patients to identify eligibility for targeted agents (olaparib, adagrasib) and immunotherapy (pembrolizumab for MSI-H/dMMR tumors). India and UAE centers in GAF Healthcare's network perform full NGS-based tumor profiling aligned with international oncology guidelines.
Candidates
• ELIGIBLE FOR SURGICAL RESECTION (Whipple / Distal Pancreatectomy / Total Pancreatectomy):
- Pathologically or radiologically confirmed pancreatic ductal adenocarcinoma, acinar cell carcinoma, or pancreatic neuroendocrine tumor (pNET)
- Radiologically resectable disease: no arterial abutment of SMA, celiac axis, or hepatic artery; no venous occlusion of SMV/portal vein beyond reconstructable limits
- ECOG Performance Status 0–1 (selected PS 2 patients at multidisciplinary team discretion)
- Adequate cardiopulmonary reserve: FEV1 >1.5 L, LVEF >50% on ECHO, no uncontrolled coronary artery disease
- Serum albumin >3.0 g/dL; bilirubin optimized to <3 mg/dL via pre-operative biliary drainage (ERCP/PTC stenting) if jaundiced
- Age: no absolute upper limit; physiological age and frailty scoring (Clinical Frailty Scale, ECOG PS) guide candidacy
• ELIGIBLE FOR BORDERLINE RESECTABLE / NEOADJUVANT PROTOCOLS:
- Venous abutment or short-segment occlusion of SMV/portal vein amenable to vascular reconstruction
- Arterial abutment (<180°) of SMA or common hepatic artery without involvement of celiac axis
- Elevated CA 19-9 (>500 U/mL) as a relative indicator for neoadjuvant chemotherapy before surgery
• ELIGIBLE FOR SYSTEMIC / PALLIATIVE THERAPY:
- Locally advanced (unresectable Stage III) or metastatic (Stage IV) disease
- BRCA1/2 or PALB2 germline mutation: eligible for maintenance olaparib (PARP inhibitor) post-platinum response
- MSI-H / dMMR tumor: eligible for pembrolizumab immunotherapy
- KRAS G12C mutation: eligible for adagrasib (investigational/compassionate use in select centers)
- NRG1 fusions, NTRK fusions: eligible for targeted therapy (entrectinib, larotrectinib)
• REQUIRED PRE-TREATMENT DIAGNOSTICS:
- Triphasic CT pancreatic protocol (0.625–1 mm slice thickness) for resectability assessment
- MRI liver with hepatobiliary contrast (gadoxetate) to exclude hepatic metastases
- EUS + Fine-Needle Biopsy (EUS-FNB) for tissue confirmation if CT-guided biopsy not feasible
- PET-CT (18F-FDG) to exclude occult distant metastases before major surgery
- Serum CA 19-9, CEA, LFTs, CBC, coagulation profile, HbA1c
- Comprehensive metabolic panel and nutritional assessment (pre-albumin, BMI, MUST score)
- Germline genetic testing (BRCA1/2, PALB2, Lynch syndrome genes) for all patients
- Tumor NGS panel (somatic) — minimum 50-gene panel recommended
- Cardiopulmonary evaluation: 12-lead ECG, ECHO (LVEF assessment), pulmonary function tests for surgical candidates
• CONTRAINDICATIONS TO SURGERY:
- Distant metastatic disease (liver, peritoneal, lung) confirmed on PET-CT
- Encasement (>270°) of SMA, celiac axis, or aorta without feasible reconstruction
- ECOG Performance Status ≥3 or severe frailty (Clinical Frailty Scale ≥6)
- Uncontrolled coagulopathy or active thromboembolic disease not amenable to bridging
- Severe malnutrition with albumin <2.5 g/dL unresponsive to nutritional optimization
Procedure
SURGICAL APPROACHES:
1. Pancreaticoduodenectomy (Whipple Procedure) — Standard & Pylorus-Preserving (PPPD):
The gold-standard curative resection for pancreatic head and uncinate process tumors. En bloc removal of the pancreatic head, duodenum, proximal jejunum, gallbladder, and common bile duct, with reconstruction via pancreaticojejunostomy, hepaticojejunostomy, and gastro/duodenojejunostomy. The pylorus-preserving modification (PPPD) maintains the stomach and pylorus, reducing post-gastrectomy complications while maintaining oncologic equivalence. Vascular resection and reconstruction of the SMV/portal vein axis (segmental resection with primary anastomosis or interposition graft) is performed in borderline resectable cases at high-volume centers.
2. Distal Pancreatectomy with Splenectomy (DP-CAM for left-sided tumors):
Standard approach for pancreatic body and tail tumors. The radical antegrade modular pancreatosplenectomy (RAMPS) technique optimizes retroperitoneal margin clearance by dissecting anterior or posterior to Gerota's fascia depending on dorsal tumor extent, improving R0 resection rates over conventional distal pancreatectomy.
3. Total Pancreatectomy:
Indicated for multifocal disease, positive pancreatic neck margin at frozen section, or main-duct IPMN with high-grade dysplasia/invasive cancer throughout the gland. Requires lifelong insulin therapy and exocrine enzyme replacement (pancreatic enzyme replacement therapy, PERT).
4. Robotic-Assisted Pancreatic Surgery (da Vinci Xi System):
Available at select GAF Healthcare partner centers in India (Mumbai, Chennai, Hyderabad) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). Robotic platforms provide 3D HD visualization, wristed instrumentation with 7 degrees of freedom, and tremor filtration — particularly advantageous for the complex pancreaticojejunostomy anastomosis in Whipple procedures and for splenic vessel dissection in distal pancreatectomy. Published data demonstrate equivalent oncologic outcomes with lower estimated blood loss and shorter hospital stay versus open surgery in experienced hands.
5. Laparoscopic (Minimally Invasive) Pancreatectomy:
Laparoscopic distal pancreatectomy is the preferred approach for left-sided tumors at most high-volume centers, offering reduced wound morbidity, shorter hospitalization, and faster return to systemic therapy. Laparoscopic Whipple, while technically demanding, is performed at select centers with demonstrated high-volume expertise.
SYSTEMIC THERAPY:
6. Neoadjuvant Chemotherapy:
• FOLFIRINOX (oxaliplatin + irinotecan + leucovorin + 5-FU): First-line regimen for fit patients (ECOG 0–1, adequate biliary drainage). Used to downstage borderline resectable disease and improve margin-negative resection rates. Modified FOLFIRINOX (mFOLFIRINOX) reduces toxicity with maintained efficacy.
• Gemcitabine + Nab-Paclitaxel (Abraxane): Preferred for patients with PS 1–2 or those less tolerant of FOLFIRINOX. Achieves tumor stroma disruption via albumin-bound paclitaxel, improving gemcitabine delivery.
7. Adjuvant Chemotherapy (post-resection):
• Modified FOLFIRINOX for 12 cycles (PRODIGE 24 trial): Superior disease-free survival versus gemcitabine alone in R0/R1 resected patients with adequate performance status.
• Gemcitabine + Capecitabine (ESPAC-4 trial): An alternative for patients not tolerating FOLFIRINOX.
8. Targeted Therapy:
• Olaparib (PARP inhibitor): Maintenance therapy for metastatic PDAC with germline BRCA1/2 mutation following ≥16 weeks of platinum-based chemotherapy without progression (POLO trial).
• Pembrolizumab (anti-PD-1 immunotherapy): For MSI-H/dMMR pancreatic cancer (~1% of cases) per NCCN Tier 1 recommendation.
• Adagrasib / Sotorasib: KRAS G12C inhibitors available via clinical trial or compassionate use at GAF Healthcare partner cancer centers.
• Entrectinib / Larotrectinib: For NTRK fusion-positive pancreatic tumors (rare but actionable).
9. Chemoradiation (CRT) and SBRT:
• Stereotactic Body Radiotherapy (SBRT): High-dose conformal radiation (typically 33–40 Gy in 5 fractions) for locally advanced unresectable PDAC, offering local control with minimal toxicity. Available with Varian TrueBeam and Elekta Versa HD linear accelerators at GAF partner centers.
• Conventional CRT (50.4 Gy + capecitabine or gemcitabine): Used as consolidation after initial chemotherapy in locally advanced disease.
10. Palliative Interventions:
• ERCP with biliary stenting (plastic or covered self-expanding metal stent, SEMS) for obstructive jaundice
• EUS-guided celiac plexus neurolysis (CPN) for refractory pain management
• Gastrojejunostomy (open or laparoscopic) or endoscopic duodenal stenting for gastric outlet obstruction
• Pancreatic Enzyme Replacement Therapy (PERT): Creon or equivalent, dosed per fat intake to manage exocrine insufficiency
Cost of Pancreatic Cancer Treatment: India vs. UAE
Pancreatic cancer treatment costs vary significantly based on the treatment modality (surgical resection vs. systemic chemotherapy), disease stage, hospital tier, and whether robotic/minimally invasive techniques are employed. The following comparison reflects all-inclusive estimates for a complete treatment episode — including surgeon fees, anesthesia, ICU stay, hospital room (private ward), standard medications, pathology, and basic nursing care — at JCI-accredited or equivalent-tier hospitals within the GAF Healthcare partner network. India consistently offers 50–65% cost savings versus the UAE and 70–80% savings versus Western Europe or North America, without compromise in oncologic outcomes at high-volume centers. UAE destinations (Dubai and Abu Dhabi) offer ultra-premium hospital environments, shorter travel from the Middle East and Africa, and seamless luxury concierge services.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $6,000 – $18,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $15,000 – $40,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2):
• Patient submits medical records (pathology report, imaging DICOM files, prior treatment summaries) to GAF Healthcare's medical team
• GAF Healthcare oncology coordinators arrange a virtual multidisciplinary tumor board (MDT) review with the treating surgeon, medical oncologist, and interventional radiologist at the selected partner hospital
• Treatment plan confirmed: surgery vs. neoadjuvant chemotherapy first vs. systemic therapy
• GAF Healthcare initiates e-Medical Visa application (India) or UAE entry visa facilitation
• Pre-travel fitness assessment: cardiology clearance, nutritional optimization, glycemic control for diabetic patients
• Arrangements: airport transfer, hospital-adjacent accommodation for 1–2 attendants
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in-country):
• Airport pickup by GAF Healthcare dedicated coordinator; hotel/guest house check-in
• Hospital admission: repeat imaging review, EUS/ERCP if biliary drainage required, repeat bloodwork
• Anesthesia pre-assessment: ECHO, PFTs, airway evaluation
• Nutritional optimization if albumin low: 5–7 days oral immunonutrition (arginine/omega-3 enriched formula)
• Multidisciplinary consent process with interpreter support arranged by GAF Healthcare
• Marking of surgical site, VTE prophylaxis planning (LMWH protocol)
• Bowel preparation and pre-operative fasting per ERAS (Enhanced Recovery After Surgery) protocol
PHASE 3 — SURGICAL PROCEDURE (Day 4–5, Operating Day):
• General anesthesia; epidural catheter placed for post-operative analgesia (open Whipple)
• Open or minimally invasive (robotic/laparoscopic) pancreatic resection performed (duration: 4–8 hours for Whipple; 2–4 hours for distal pancreatectomy)
• Intraoperative frozen-section margin analysis of pancreatic neck, bile duct, and retroperitoneal margins
• Vascular reconstruction if SMV/portal vein involved
• Closed-suction drains placed near pancreatic anastomosis
• Patient extubated in OR or transferred to ICU for overnight monitoring
PHASE 4 — IMMEDIATE POST-OPERATIVE RECOVERY (Days 1–5 post-surgery, ICU/HDU → Ward):
• Day 1: ICU monitoring; epidural or IV PCA analgesia; NGT decompression; drain amylase measured on Day 1 and Day 3 to screen for Post-Operative Pancreatic Fistula (POPF) per ISGPS criteria
• Day 2: Mobilization with physiotherapy; epidural removed if pain controlled; oral sips commenced (ERAS protocol)
• Day 3: Soft diet initiated; drain outputs reviewed; octreotide commenced if drain amylase elevated (biochemical leak management)
• Day 4–5: Escalation to semi-solid diet; VTE prophylaxis (LMWH) continued; drain removal if output <200 mL/day and amylase normalized
• Delayed gastric emptying (DGE): managed with prokinetics (metoclopramide, erythromycin) and prolonged nasogastric drainage if required
PHASE 5 — HOSPITAL DISCHARGE & IN-COUNTRY RECOVERY (Days 7–14 post-surgery):
• Discharge criteria: tolerating oral diet, pain controlled on oral analgesics, no fever, stable labs
• Pancreatic enzyme replacement therapy (PERT) initiated and dose-titrated
• Blood glucose monitoring and insulin regimen established with diabetologist
• Patient stays in GAF-arranged accommodation (hotel or serviced apartment) near hospital for 2–4 weeks
• Outpatient wound review at Day 10–14; staple/suture removal
• Post-operative CT or MRI at Week 3–4 to assess anastomotic integrity and exclude early complications
• CA 19-9 measured at Week 4 as post-resection baseline
PHASE 6 — ONCOLOGY FOLLOW-UP & FIT-TO-FLY ASSESSMENT (Weeks 4–8):
• Medical oncology consultation for adjuvant chemotherapy planning (mFOLFIRINOX or gemcitabine + capecitabine)
• Nutritional review: target weight stabilization, PERT dose finalization, vitamin D/B12/fat-soluble vitamin supplementation
• Fit-to-fly assessment by treating surgeon: typically cleared at 4–6 weeks post-Whipple, 3–4 weeks post-laparoscopic distal pancreatectomy
• GAF Healthcare coordinates medical summary, operative report, pathology report, and imaging CD for home oncologist
• Airport wheelchair assistance and in-flight medical documentation arranged by GAF Healthcare if required
PHASE 7 — LONG-TERM FOLLOW-UP (Home Country, Months 3–60):
• Adjuvant chemotherapy: 6 months total (12 cycles mFOLFIRINOX or 6 cycles gemcitabine/capecitabine)
• Surveillance imaging: CT chest/abdomen/pelvis every 3–6 months for 2 years, then 6–12 monthly
• CA 19-9 monitoring at each follow-up
• GAF Healthcare tele-oncology coordination: home oncologist receives full case file; follow-up teleconsult with India/UAE surgeon available at 3 and 12 months
Risks & Considerations
Pancreatic cancer treatment carries a meaningful spectrum of procedural and oncologic risks that patients must understand transparently. For the Whipple procedure (pancreaticoduodenectomy), the most clinically significant complication is Post-Operative Pancreatic Fistula (POPF), occurring in 10–25% of cases and classified Grade A (biochemical leak), B (requiring intervention), or C (life-threatening) per ISGPS criteria; Grade B/C fistulas may require percutaneous drain insertion, radiologic intervention, or re-operation. Delayed Gastric Emptying (DGE) affects 20–30% of patients, prolonging hospital stay by 5–10 days on average and requiring nutritional support via nasojejunal feeding. Post-pancreatectomy haemorrhage (PPH) is rare (<5%) but potentially life-threatening, with sentinel bleed from the gastroduodenal artery stump being a recognized early warning. Bile leak occurs in approximately 5–10% of cases and is managed with ERCP stenting or percutaneous drainage in most instances. Total pancreatectomy mandates lifelong insulin-dependent diabetes management and carries risks of severe brittle hypoglycemia, necessitating experienced endocrinology support. General surgical risks include wound infection (10–15%), pulmonary complications including pneumonia and atelectasis (10%), deep vein thrombosis and pulmonary embolism (3–5% despite prophylaxis), and anastomotic stricture requiring late endoscopic intervention. For systemic chemotherapy, FOLFIRINOX carries significant cumulative neurotoxicity (peripheral neuropathy in >50% of patients), myelosuppression with febrile neutropenia risk (5–10%), and severe diarrhea and fatigue; dose modifications are routine. Gemcitabine-nab-paclitaxel carries risks of peripheral neuropathy, myelosuppression, and alopecia. PARP inhibitors (olaparib) are associated with anemia, nausea, and rare pneumonitis. Oncologically, even after R0 resection, the 5-year overall survival remains 20–25% for Stage I–II disease, and patients must be counseled about the high recurrence risk (70–80% within 2 years), most commonly to the liver and peritoneum. At GAF Healthcare partner hospitals, all patients undergo pre-operative MDT review, intraoperative frozen section margin analysis, and post-operative care within ERAS protocols, which collectively reduce major complication rates and improve recovery benchmarks compared to non-specialized centers.
Top Hospitals for Pancreatic Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Pancreatic Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Amit Chopde
MBBS, DNB (General Surgery), DNB (Surgical Gastroenterology), HBNI Fellowship (GI and HPB Onco Surgery), Fellowship (HPB and Liver Transplant Surgery)
Hepatobiliary & Pancreatic Surgeon
Gleneagles Hospital, Mumbai, India
12+ Yearsof experience
Dr. Amit Chopde is a Consultant in Surgical Gastroenterology and Hepatobiliary & Pancreatic Surgeon at Gleneagles Hospital, Mumbai, with over 12 years of specialised surgical experience. He holds advanced qualifications including MBBS, DNB in General Surgery, DNB in Surgical Gastroenterology, and a prestigious HBNI Fellowship in GI and HPB Oncology Surgery from Tata Memorial Hospital, Mumbai, along with specialised training in Hepatobiliary and Liver… Read more
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Frequently Asked Questions — Pancreatic Cancer Treatment
The total cost of pancreatic cancer treatment varies by stage, treatment modality, and hospital tier. For a complete surgical episode (Whipple procedure or distal pancreatectomy including surgeon's fee, anesthesia, ICU care, private ward stay, pathology, and standard medications) at a JCI- or NABH-accredited hospital in India, the all-inclusive cost typically ranges from USD 6,000 to USD 18,000 — with robotic-assisted Whipple procedures and complex vascular reconstruction at the higher end. The same treatment at JCI- and DHA-licensed hospitals in Dubai or Abu Dhabi ranges from USD 15,000 to USD 40,000, reflecting premium infrastructure and higher operational costs in the UAE. For systemic chemotherapy-only programs (e.g., FOLFIRINOX or gemcitabine-nab-paclitaxel for locally advanced or metastatic disease), per-cycle costs in India range from USD 800–2,500 and in the UAE from USD 2,500–6,000 per cycle depending on the drug regimen. Targeted therapies (e.g., olaparib for BRCA-mutated cases) and NGS tumor profiling costs are additional. GAF Healthcare provides a personalized cost estimate within 48 hours of receiving the patient's medical records, with no hidden fees.
The required in-country stay depends primarily on the treatment modality. For patients undergoing a Whipple procedure (pancreaticoduodenectomy) or distal pancreatectomy, the hospital stay is typically 7–14 days, followed by a mandatory post-discharge recovery period near the hospital for outpatient monitoring. Most pancreatic surgery patients are cleared as fit-to-fly at 4–6 weeks post-operatively, once the treating surgeon confirms: stable nutritional intake and tolerability of oral diet; no active drain, wound complication, or signs of fistula; adequate pain control on oral analgesics; and normal or acceptable post-operative imaging (CT at Week 3–4). Patients who undergo laparoscopic distal pancreatectomy (less invasive) may be cleared earlier, typically at 3–4 weeks. The total recommended in-country stay for surgical patients is therefore 5–8 weeks. For patients receiving chemotherapy initiation only (without surgery), the in-country stay is shorter — typically 2–3 weeks to complete the first cycle, assess tolerance, and receive oncology follow-up — before returning home to continue treatment locally. GAF Healthcare arranges a formal fit-to-fly assessment and provides the patient with a structured medical travel certificate, in-flight positioning guidelines, and LMWH (blood-clot prevention injection) instructions for long-haul flights, which are typically required for 5–7 days post-travel in post-surgical oncology patients.
Success rates in pancreatic cancer treatment are stage-dependent and must be interpreted with clinical context. For surgically resected Stage I–II pancreatic ductal adenocarcinoma (PDAC) at high-volume centers (defined as >20 Whipple procedures annually), the 5-year overall survival rate is approximately 20–30%, with R0 (margin-negative) resection being the single most important prognostic factor. Median overall survival after resection followed by adjuvant modified FOLFIRINOX is 54 months (PRODIGE 24 trial), representing a major improvement over historical benchmarks. For borderline resectable disease treated with neoadjuvant FOLFIRINOX followed by surgery, 5-year survival rates of 25–30% are achievable in patients achieving a complete resection. For locally advanced (Stage III) unresectable PDAC, the median overall survival with current multimodal chemoradiation protocols is 12–20 months, with a subset of patients — particularly those with exceptional responses to FOLFIRINOX — becoming secondarily resectable and achieving long-term survival. For metastatic (Stage IV) PDAC, current systemic therapy achieves a median overall survival of 8–12 months with FOLFIRINOX or gemcitabine-nab-paclitaxel; however, molecularly selected subgroups fare significantly better — for example, BRCA1/2-mutated patients on maintenance olaparib achieve a median progression-free survival of 7.4 months versus 3.8 months on placebo (POLO trial), and MSI-H patients receiving pembrolizumab may achieve durable responses. GAF Healthcare partner centers in India and the UAE perform full molecular tumor profiling for every patient to identify all actionable targets, maximizing individualized treatment benefit.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive, white-glove medical travel coordination for international patients pursuing pancreatic cancer treatment in India or the UAE, covering every logistical need from first inquiry to departure.
VISA & ENTRY DOCUMENTATION: For India: GAF Healthcare's dedicated visa team prepares and submits the complete e-Medical Visa application on the patient's behalf, including the mandatory hospital invitation letter from the partner hospital, appointment confirmation, and financial documentation. India's e-Medical Visa is processed within 1–3 business days and permits a stay of up to 60 days (extendable in-country), with provision for one accompanying attendant on an e-Medical Attendant Visa. For the UAE (Dubai / Abu Dhabi): Nationals of over 60 countries receive visa-on-arrival or visa-free access to the UAE. For all other nationalities, GAF Healthcare facilitates a UAE Medical Treatment Visa application supported by the hospital's official treatment plan, DHA-licensed hospital letter, and financial guarantee. UAE medical visas are typically processed within 5–7 working days.
AIRPORT & GROUND TRANSFERS: Dedicated, medically informed chauffeur transfers are arranged for all arrival and departure journeys. Vehicles are wheelchair-accessible and equipped with basic medical supplies for post-operative patients. All drivers are briefed on the patient's condition and hospital destination. Same-day transfer from airport to hospital or to GAF-arranged accommodation is guaranteed.
ACCOMMODATION FOR PATIENTS AND ATTENDANTS: GAF Healthcare negotiates preferred rates at hospital-adjacent serviced apartments, guest houses, and hotels to accommodate patients during the post-discharge recovery period (typically 3–6 weeks for pancreatic surgery). Options range from budget-friendly hospital guest houses to 4–5 star medically proximate hotels. All accommodations are selected for proximity (<10 minutes) to the treating hospital for outpatient follow-up visits. Arrangements for 1–2 family attendants are included as standard.
DEDICATED INTERPRETER & PATIENT COORDINATOR: A dedicated bilingual patient coordinator (fluent in English plus the patient's native language as applicable) is assigned from the point of inquiry through discharge. Interpreters are available for Arabic, Russian, Swahili, French, and other major languages. The coordinator accompanies patients to key clinical appointments, translates informed consent discussions, and liaises between the clinical team and the patient's family in real time.
MEDICAL RECORD TRANSFER & TELE-COORDINATION: GAF Healthcare's clinical team performs initial remote case review of all submitted DICOM imaging and histopathology reports before travel is confirmed. On discharge, a comprehensive medical dossier — including operative notes, histopathology (including margin status, lymph node count, and molecular profiling results), imaging CDs, discharge summary, and adjuvant therapy plan — is prepared in English and handed to the patient and shared electronically with their home oncologist. Teleconsultation follow-up with the treating surgeon and oncologist is available at 4 weeks and 3 months post-discharge via GAF Healthcare's tele-oncology platform.
Patients Also Explore
Other treatments commonly sought by patients considering Pancreatic Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology